Accunea

Executive Summary

Accunea is a UK-based medical technology company founded in 2020 that is developing real-time biosensing technology to improve outcomes in organ transplantation. The company's primary focus is on reducing kidney transplant discard and failure rates by providing clinicians with dynamic molecular insights into organ viability and function. By enabling continuous monitoring of organ condition, Accunea aims to ensure that every donated organ is used effectively and that patient recovery is optimized. The company is still in early stages, with no disclosed funding or product commercialization, but its innovative approach addresses a critical unmet need in transplantation. As the organ shortage crisis persists, Accunea's technology could transform transplant logistics and patient care, potentially reducing costs and improving survival rates. The company's progress will depend on successful clinical validation and securing regulatory approvals.

Upcoming Catalysts (preview)

• Q4 2026First-in-human clinical study initiation for kidney transplant monitoring40% success
• Q2 2027Series A funding round closure60% success
• Q1 2027Grant of CE mark or FDA breakthrough device designation35% success